Home Featured Page 5

Featured

Latest

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Utah’s Quiet Revolution: Why HB 390 May Be the Most Significant...

EDITOR PICKS

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

Weekly Psychedelic Policy Briefing – August 9, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Utah’s Quiet Revolution: Why HB 390 May Be the Most Significant...

EDITOR PICKS

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

Weekly Psychedelic Policy Briefing – August 9, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY